S&P 500   4,580.44 (+0.12%)
DOW   35,760.55 (+0.01%)
QQQ   381.05 (+0.51%)
AAPL   148.90 (-0.28%)
MSFT   318.85 (+2.82%)
FB   316.55 (+0.23%)
GOOGL   2,830.30 (+1.58%)
TSLA   1,053.11 (+3.41%)
AMZN   3,411.35 (+1.05%)
NVDA   248.01 (+0.34%)
BABA   172.23 (+1.32%)
NIO   41.22 (+1.85%)
CGC   13.30 (+0.99%)
GE   105.00 (-2.27%)
AMD   126.37 (+2.80%)
MU   68.56 (-0.55%)
T   25.32 (-0.20%)
F   15.74 (-1.25%)
ACB   7.09 (+0.85%)
DIS   170.46 (-0.92%)
PFE   43.27 (-0.67%)
BA   209.48 (-0.16%)
AMC   36.14 (+0.25%)
S&P 500   4,580.44 (+0.12%)
DOW   35,760.55 (+0.01%)
QQQ   381.05 (+0.51%)
AAPL   148.90 (-0.28%)
MSFT   318.85 (+2.82%)
FB   316.55 (+0.23%)
GOOGL   2,830.30 (+1.58%)
TSLA   1,053.11 (+3.41%)
AMZN   3,411.35 (+1.05%)
NVDA   248.01 (+0.34%)
BABA   172.23 (+1.32%)
NIO   41.22 (+1.85%)
CGC   13.30 (+0.99%)
GE   105.00 (-2.27%)
AMD   126.37 (+2.80%)
MU   68.56 (-0.55%)
T   25.32 (-0.20%)
F   15.74 (-1.25%)
ACB   7.09 (+0.85%)
DIS   170.46 (-0.92%)
PFE   43.27 (-0.67%)
BA   209.48 (-0.16%)
AMC   36.14 (+0.25%)
S&P 500   4,580.44 (+0.12%)
DOW   35,760.55 (+0.01%)
QQQ   381.05 (+0.51%)
AAPL   148.90 (-0.28%)
MSFT   318.85 (+2.82%)
FB   316.55 (+0.23%)
GOOGL   2,830.30 (+1.58%)
TSLA   1,053.11 (+3.41%)
AMZN   3,411.35 (+1.05%)
NVDA   248.01 (+0.34%)
BABA   172.23 (+1.32%)
NIO   41.22 (+1.85%)
CGC   13.30 (+0.99%)
GE   105.00 (-2.27%)
AMD   126.37 (+2.80%)
MU   68.56 (-0.55%)
T   25.32 (-0.20%)
F   15.74 (-1.25%)
ACB   7.09 (+0.85%)
DIS   170.46 (-0.92%)
PFE   43.27 (-0.67%)
BA   209.48 (-0.16%)
AMC   36.14 (+0.25%)
S&P 500   4,580.44 (+0.12%)
DOW   35,760.55 (+0.01%)
QQQ   381.05 (+0.51%)
AAPL   148.90 (-0.28%)
MSFT   318.85 (+2.82%)
FB   316.55 (+0.23%)
GOOGL   2,830.30 (+1.58%)
TSLA   1,053.11 (+3.41%)
AMZN   3,411.35 (+1.05%)
NVDA   248.01 (+0.34%)
BABA   172.23 (+1.32%)
NIO   41.22 (+1.85%)
CGC   13.30 (+0.99%)
GE   105.00 (-2.27%)
AMD   126.37 (+2.80%)
MU   68.56 (-0.55%)
T   25.32 (-0.20%)
F   15.74 (-1.25%)
ACB   7.09 (+0.85%)
DIS   170.46 (-0.92%)
PFE   43.27 (-0.67%)
BA   209.48 (-0.16%)
AMC   36.14 (+0.25%)
OTCMKTS:PURE

PURE Bioscience Stock Forecast, Price & News

$0.39
+0.02 (+5.45 %)
(As of 10/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.38
$0.39
50-Day Range
$0.29
$0.42
52-Week Range
$0.27
$1.40
Volume48,200 shs
Average Volume43,108 shs
Market Capitalization$33.78 million
P/E RatioN/A
Dividend YieldN/A
Beta0.03
30 days | 90 days | 365 days | Advanced Chart
Receive PURE News and Ratings via Email

Sign-up to receive the latest news and ratings for PURE Bioscience and its competitors with MarketBeat's FREE daily newsletter.


PURE Bioscience logo

About PURE Bioscience

PURE Bioscience, Inc. engages in the discovery, development, and commercialization of proprietary antimicrobial products for pathogen and hygienic control. It offers silver dihydrogen citrate-based disinfecting and sanitizing products. The company was founded by Michael L. Krall on August 24, 1992 and is headquartered in Rancho Cucamonga, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Miscellaneous chemical products
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:PURE
Employees
11
Year Founded
N/A

Sales & Book Value

Annual Sales
$6.92 million
Cash Flow
$0.00 per share
Book Value
$0.06 per share

Profitability

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$33.78 million
Next Earnings Date
N/A
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.24 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -












PURE Bioscience (OTCMKTS:PURE) Frequently Asked Questions

What stocks does MarketBeat like better than PURE Bioscience?

Wall Street analysts have given PURE Bioscience a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but PURE Bioscience wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting PURE Bioscience?

PURE Bioscience saw a decline in short interest in the month of September. As of September 30th, there was short interest totaling 3,800 shares, a decline of 86.9% from the September 15th total of 29,100 shares. Based on an average daily volume of 49,700 shares, the short-interest ratio is currently 0.1 days.
View PURE Bioscience's Short Interest
.

How were PURE Bioscience's earnings last quarter?

PURE Bioscience, Inc. (OTCMKTS:PURE) issued its earnings results on Thursday, March, 12th. The company reported ($0.01) EPS for the quarter. The company had revenue of $0.35 million for the quarter. PURE Bioscience had a negative trailing twelve-month return on equity of 5.84% and a negative net margin of 3.76%.
View PURE Bioscience's earnings history
.

How has PURE Bioscience's stock price been impacted by Coronavirus?

PURE Bioscience's stock was trading at $0.5389 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PURE shares have decreased by 28.1% and is now trading at $0.3873.
View which stocks have been most impacted by COVID-19
.

Who are PURE Bioscience's key executives?

PURE Bioscience's management team includes the following people:
  • Tom Y. Lee, Chairman, President & Chief Executive Officer
  • Tom Myers, Chief Operating Officer & Director
  • Mark S. Elliott, VP, Chief Financial & Accounting Officer
  • Dolana Blount, VP-Technology Development & Regulatory Affairs

What other stocks do shareholders of PURE Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PURE Bioscience investors own include NVIDIA (NVDA), The Boeing (BA), Overstock.com (OSTK), Pure Storage (PSTG), Riot Blockchain (RIOT), Enphase Energy (ENPH), Mastercard (MA), Main Street Capital (MAIN), Twilio (TWLO) and (CGC).

What is PURE Bioscience's stock symbol?

PURE Bioscience trades on the OTCMKTS under the ticker symbol "PURE."

How do I buy shares of PURE Bioscience?

Shares of PURE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PURE Bioscience's stock price today?

One share of PURE stock can currently be purchased for approximately $0.39.

How much money does PURE Bioscience make?

PURE Bioscience has a market capitalization of $33.78 million and generates $6.92 million in revenue each year.

How many employees does PURE Bioscience have?

PURE Bioscience employs 11 workers across the globe.

What is PURE Bioscience's official website?

The official website for PURE Bioscience is www.purebio.com.

Where are PURE Bioscience's headquarters?

PURE Bioscience is headquartered at 9669 HERMOSA AVENUE, RANCHO CUCAMONGA CA, 91730.

How can I contact PURE Bioscience?

PURE Bioscience's mailing address is 9669 HERMOSA AVENUE, RANCHO CUCAMONGA CA, 91730. The company can be reached via phone at (619) 596-8600 or via email at [email protected].


This page was last updated on 10/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.